Implications of cytochrome P450 2C9 polymorphism on warfarin metabolism and dosing.
about
Limitations of traditional anticoagulants.Revisiting the significance of warfarin protein-binding displacement interactions.Evaluation of genetic factors for warfarin dose predictionInteraction of warfarin with drugs, natural substances, and foods.The pharmacogenetics of coumarin therapy.Rosuvastatin: a highly potent statin for the prevention and management of coronary artery disease.Pharmacotherapy of atrial fibrillation: an old option with new possibilities.Probable metabolic interaction of doxifluridine with phenytoin.In vivo and in vitro disposition profile of tezosentan, an intravenous dual endothelin receptor antagonist, in humans.The influence of ethnicity on warfarin dosage requirement.Effect of rosuvastatin on warfarin pharmacodynamics and pharmacokinetics.Inadvertent exaggerated anticoagulation following use of bismuth subsalicylate in an enterally fed patient receiving warfarin therapy.
P2860
Q33362181-C6B3651E-839B-422F-8172-D70BBCC713BCQ34153426-5B16C45C-E4DC-4EA4-84FE-3D6E312EF29EQ35758421-DF6E6384-7BF7-4158-9E9D-965F64F919C5Q36007599-0A92D689-D180-4FB3-BD40-0CD6C9937921Q36192806-E31D216D-9AFE-4A15-881B-21505AD7C94EQ36752063-BF552416-3462-48A8-A229-D86FEC09946DQ37123391-B3198B64-DCDE-4FBA-9606-25D283D79B87Q43972195-A6392ED2-7724-4769-B3EB-9ABC9F73BFD5Q44440246-D3C007BA-61D0-4B6C-B1B4-490ECA2F592CQ46458606-208C8005-3DEA-41EE-AE09-32A4AAE47649Q46607005-A17E85CE-7C0F-480B-85C6-C5BC9884D82CQ51190068-31B75C31-6B7E-4E63-802F-6A62760877B7
P2860
Implications of cytochrome P450 2C9 polymorphism on warfarin metabolism and dosing.
description
2001 nî lūn-bûn
@nan
2001 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Implications of cytochrome P450 2C9 polymorphism on warfarin metabolism and dosing.
@ast
Implications of cytochrome P450 2C9 polymorphism on warfarin metabolism and dosing.
@en
type
label
Implications of cytochrome P450 2C9 polymorphism on warfarin metabolism and dosing.
@ast
Implications of cytochrome P450 2C9 polymorphism on warfarin metabolism and dosing.
@en
prefLabel
Implications of cytochrome P450 2C9 polymorphism on warfarin metabolism and dosing.
@ast
Implications of cytochrome P450 2C9 polymorphism on warfarin metabolism and dosing.
@en
P2860
P1433
P1476
Implications of cytochrome P450 2C9 polymorphism on warfarin metabolism and dosing.
@en
P2093
P2860
P304
P356
10.1592/PHCO.21.2.235.34106
P407
P577
2001-02-01T00:00:00Z